NCT02588716View on ClinicalTrials.gov

Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

December 31, 2016

Conditions
Hepatectomy, Surgical Blood Loss, Terlipressin
Interventions
DRUG

Terlipressin

Terlipressin will be given as an intravenous injection of 2μg/kg/h to be continued throughout the surgery and weaned off over four hours postoperatively.

DRUG

normal saline

Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.

Trial Locations (1)

11111

Assiut University hospital, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT02588716 - Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection. | Biotech Hunter | Biotech Hunter